2015
DOI: 10.1002/14651858.cd005538.pub3
|View full text |Cite
|
Sign up to set email alerts
|

Diclofenac for acute pain in children

Abstract: The editorial group responsible for this previously published document have withdrawn it from publication.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0
2

Year Published

2018
2018
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 134 publications
0
3
0
2
Order By: Relevance
“…Diclofenac is not approved to treat patients below 18 years . The analysis shows that 74 prescriptions were dispensed for patients younger than 18 years, which on average is 1.9% of off‐label use of diclofenac . It is representative as the range of distribution of off‐label prescriptions between the pharmacies only varied with a factor 1.8.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Diclofenac is not approved to treat patients below 18 years . The analysis shows that 74 prescriptions were dispensed for patients younger than 18 years, which on average is 1.9% of off‐label use of diclofenac . It is representative as the range of distribution of off‐label prescriptions between the pharmacies only varied with a factor 1.8.…”
Section: Resultsmentioning
confidence: 99%
“…Though, for quetiapine, mirtazapine and diclofenac, the off‐label use for children equals 2% (145 prescriptions out of 7518). The ADR profile may be the same as in adults, but it has not been examined for children .…”
Section: Discussionmentioning
confidence: 99%
“…8 A Cochrane systematic review published in 2015 investigated the efficacy and safety of diclofenac for acute pain in children. 9 In the analysis of serious adverse events, there were 74 trials of 3611 children, of whom 26 experienced serious adverse events. Twenty-two gastrointestinal complications and two fatalities were identified from case reports.…”
Section: Contraindications With Intravenous Usementioning
confidence: 99%
“…Associé aux morphiniques ou aux AINS, le paracétamol présente un effet antalgique additif ou synergique [16,54] (niveau de preuve 1). L'administration de paracétamol par voie intraveineuse ou dès que possible per os, est recommandée en association, dans la prise en charge de la douleur post-amygdalectomie [7,28] (niveau de preuve 1).…”
Section: Rappels Concernant Le Paracétamolunclassified
“…Ratio bénéfice-risque des anti-inflammatoires non stéroïdiens (AINS)Comparés au paracétamol ou à un placebo, les AINS procurent une antalgie supérieure avec une diminution des NVPO[15] (niveau de preuve 1). Dans le contexte post-amygdalectomie, l'utilisation de l'association paracétamol-AINS est plus efficace que l'utilisation isolée d'un des deux produits[16] (niveau de preuve 1). Comparés à l'association codéine-paracétamol, les AINS (ibuprofène) présentent des effets antalgiques similaires avec une moindre incidence des vomissements[17] (niveau de preuve 2).Leur principal inconvénient est leur interaction avec les processus de la coagulation (altération de l'hémostase primaire par…”
unclassified